...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study
【24h】

Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study

机译：利妥昔单抗与霉酚酸酯和环磷酰胺脉冲治疗活动性狼疮性肾炎的临床观察

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. We report the first comparison between rituximab (RTX) and either MMF or CYC pulses in the treatment of active LN. Methods. Fifty-four patients with active LN received three methylprednisolone pulses for 3 consecutive days followed by oral prednisone and RTX 1 g at days 3 and 18 (17 patients) or MMF 2-2.5 g/day (17 patients) or six CYC pulses (0.5 g every fortnight) (20 patients). At 4 months MMF, AZA or ciclosporin were associated to prednisone as a consolidation/maintenance therapy in all groups. The outcomes of the three groups were compared at 3 and 12 months. Results. Patients in the RTX group were older, had a longer duration of SLE and LN, had more renal flares, had higher activity and had higher chronicity indexes at renal biopsy than the other two groups. Four patients in each group had acute renal dysfunction and ～50% had nephrotic syndrome. At 3 months, proteinuria was reduced by 50% in 58.8% of patients on RTX, in 64.7% on MMF and in 63.1% on CYC. At 12 months, complete remission was present in 70.6% of patients on RTX, in 52.9% on MMF, and in 65% on CYC. Partial remission was reached in 29.4% on RTX, 41.2% on MMF, and 25% on CYC. Conclusion. RTX seems to be at least as effective as MMF and CYC pulses in inducing remission. Considering that patients treated with RTX had more negative renal prognostic factors, this drug should be considered a viable alternative for the treatment of active LN.
机译：目的。我们报告了利妥昔单抗（RTX）与MMF或CYC脉冲在活动性LN治疗中的首次比较。方法。 54名活动性LN患者连续3天接受3次甲基强的松龙脉冲治疗，然后在第3和18天口服泼尼松和RTX 1 g（17例患者）或MMF 2-2.5 g /天（17例患者）或6次CYC脉冲（0.5 g每两周一次）（20位患者）。在所有组中，在4个月时，MMF，AZA或环孢素与泼尼松联合作为巩固/维持疗法。在3个月和12个月时比较了三组的结果。结果。与其他两组相比，RTX组的患者年龄更大，SLE和LN的病程更长，肾脏耀斑多，活动度更高和慢性活检的慢性指数更高。每组有4例患有急性肾功能不全，约50％患有肾病综合征。在3个月时，接受RTX的58.8％患者的蛋白尿减少了50％，MMF减少了64.7％，CYC减少了63.1％。在12个月时，接受RTX的患者中70.6％的患者完全缓解，MMF患者中52.9％的患者，CYC患者中的缓解率为65％。 RTX的部分缓解率为29.4％，MMF的部分缓解率为41.2％，CYC的部分缓解率为25％。结论。 RTX在诱导缓解方面似乎至少与MMF和CYC脉冲一样有效。考虑到接受RTX治疗的患者的肾脏预后更多，因此该药物应被视为治疗活动性LN的可行替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号